YBO Stock Overview
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Tenax Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.11 |
52 Week High | US$13.80 |
52 Week Low | US$1.50 |
Beta | 2.15 |
1 Month Change | 0% |
3 Month Change | -94.55% |
1 Year Change | -99.19% |
3 Year Change | -99.08% |
5 Year Change | -99.91% |
Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
YBO | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0% | 3.3% | 1.6% |
1Y | -99.2% | 35.8% | 6.4% |
Return vs Industry: YBO underperformed the German Biotechs industry which returned -23.4% over the past year.
Return vs Market: YBO underperformed the German Market which returned 6.3% over the past year.
Price Volatility
YBO volatility | |
---|---|
YBO Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 5.9% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: YBO's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine YBO's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1967 | 9 | Chris Giordano | https://www.tenaxthera.com |
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014.
Tenax Therapeutics, Inc. Fundamentals Summary
YBO fundamental statistics | |
---|---|
Market cap | €3.47m |
Earnings (TTM) | -€10.72m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs YBO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
YBO income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$11.71m |
Earnings | -US$11.71m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -1.26 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did YBO perform over the long term?
See historical performance and comparison